It has been acknowledged that a prothrombotic tendency may result from a specific genetic defect. Resistance to activated protein C (APC) (factor V Leiden) is now recognized as the most prevalent cause of increased thrombogenicity, being found in 2% to 5% of the world population. The APC-resistant phenotype arises from a well-characterized transitional mutation, resulting in an arginine(R)-506-glutamine(Q) amino acid substitution. Much remains to be uncovered concerning the importance of this mutation and how it relates to other conditions on a broader basis. Relevant and accurate detection methods that quickly identify the genetic lesion will play a major part in this strategy. This article details recent advances in identifying the factor V Leiden mutation by modern molecular techniques.
Get full access to this article
View all access options for this article.
References
1.
Guinto ER, Esmon CT, Mann KG: The complete cDNA sequence of bovine coagulation factor V. J Biol Chem267:2971-2978, 1992
2.
Kalafatis M. , Lu D., Bertina RM: Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden. Arterioscler Thromb Vasc Biol15:2181-2187, 1995
3.
Jenny RJ, Pittman DD, Toole JJ: Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA84:4846-4850, 1987
4.
de Stefano V. , Leone G.: Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia. Haematologica80:344-356, 1995
5.
Zöller B., Holm J., Dahlbäck B.: Resistance to activated protein C due to a factor V gene mutation. The most common inherited risk factor of thrombosis. Trends Cardiovasc Med6:45-53, 1996
6.
Dahlbäck B., Hildebrand B.: Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA91:1396-1400, 1994
7.
Dahlbäck B., Hillarp A., Rosen S.: Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis . Ann Haematol72:166-176, 1996
8.
Dahlbäck B., Carlsson M., Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA90:1004-1008, 1993
9.
Hajjar KA: Factor V Leiden—An unselfish gene?N Engl J Med331, 23:1585-1587, 1994 (editorial)
10.
Bertina RM, Koeleman Bpc, Koster T.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature369:64-67, 1994
11.
Koster T., Rosendaal FR, de Ronde H.: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet342:1503-1506, 1993
12.
Beauchamp NJ , Daly ME, Hampton KK: High prevalence of a mutation in the factor V gene within the U.K. population: Relationship to activated protein C resistance and familial thrombosis. Br J Haematol88:219-222, 1994
13.
Voorberg J. , Roelse J., Koopman R.: Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor VLancet343:1535-1538, 1994
14.
Dahlbäck B. : Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost73:739-742, 1995
15.
Sun X., Evatt B., Griffin JH: Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood83:3120-3125, 1994
16.
Svensson PJ , Dahlbäck B.: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med330:517-522, 1994
17.
Kirschbaum NE, Foster PA: The polymerase chain reaction with sequence-specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thromb Haemost74:874-878, 1995
18.
Wang H., Riddell DC, Guinto ER: Localization of the gene encoding human factor V gene to chromosome 1q21-25 . Genomics2:234-328, 1988
19.
Cripe LD, Moore KD, Kane WH: Structure of the gene for human coagulation factor V. Biochemistry31:3777-3785, 1992
20.
Greengard JS , Sun X., Xu X.: Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet343:1361-1362, 1994
21.
Zöller B., Dahlbäck B.: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet343:1536-1538, 1994
22.
Zöller B., Svensson PJ, He X.: Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C . J Clin Invest94:2521-2524, 1994
23.
Kalafatis M. , Rand MD, Mann KG: The mechanism of inactivation of human factor V and human factor Va by activated proteinC. J Biol Chem269:31869-31880, 1994
24.
Heeb MJ, Kojima Y., Greengard JS: Activated protein C resistance: Molecular mechanisms based on studies using purified Gln506-factor V. Blood85:3405-3411, 1995
25.
Koeleman Bpc , Reitsma PH, Allaart CF: Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood84:1031-1035, 1994
26.
Braun A., Müller B., Rosche AA: Population study of the G1691A mutation (R506Q, FV Leiden) in the human factor V gene that is associated with resistance to activated protein C. Hum Genet97:263-264, 1996
27.
Dahlbäck B. : New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost74:139-148, 1995
28.
ReesDc, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet346:1133-1134, 1995
29.
de Ronde H. , Bertina RM: Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria . Thromb Haemost72:880-886, 1994
30.
Brenner B., Lanir N., Thaler I.: HELLP syndrome associated with factor V R506Q mutation. Br J Haematol92:999-1001, 1996
31.
Levoir D., Emmerich J., Alhenc-Gelas M.: Portal vein thrombosis and factor V Arg 506 to Gln mutation. Thromb Haemost73:550-551, 1995
32.
Linna T., Ylikorkala A., Kontula K.: Prevalence of factor V Leiden in young adults with retinal vein occlusion . Thromb Haemost77:214-216, 1997
33.
Holm J., Zöller B., Svensson PJ: Myocardial infarction associated with homozygous resistance to activated protein C. Lancet344:952-953, 1994
34.
Samani NJ, Lodwick D., Martin D.: Resistance to activated protein C and risk of premature myocardial infarction . Lancet344:1709-1710, 1994
35.
de Lucia D. , Puca GA, Molinari AM: A rapid PCR screening method to detect factor V Leiden mutation in arterial brain thromboses. Br J Haematol93:743, 1996 (abstr)
36.
Syrjälä M., Tatlisumak T., Lindsberg P.: FV Arg-506-Gln mutation in ischemic stroke. Thromb Haemost73:1124, 1995
37.
Nowak-Göttl U., Koch HG, Aschka I.: Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol92:992-998, 1996
38.
Heinrich J. , Schulte H., Funke H.: Frequency of point mutation in factor V gene (1691 G/A), which is associated with resistance to activated protein C, in coronary artery disease patients. Thromb Haemost73:1125, 1995
39.
Prohaska W. , Mannebach H., Schmidt M.: Evidence against heterozygous coagulation factor V 1691 G→A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction . Mol Med73:521-524,1995
40.
Ridker PM, Hennekens CH, Lindpaintner K.: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med332:912-917, 1995
41.
Rosendaal FR , Koster T., Vandenbroucke JP: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) . Blood85:1504-1508, 1995
42.
Fauno P., Raun HB, Lassen JF: Association between activated protein C resistance and postoperative deep vein thrombosis. Thromb Haemost73:1371, 1995
43.
Bauer KA: Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost74:94-100, 1995
44.
Conard J., Trossaërt M., Horellou MH: Risk of venous thrombosis in 51 women with resistance to activated protein C associated with factor V Leiden. Thromb Haemost73:1375, 1995 (abstr)
45.
Vandenbroucke JP, Koster T., Briet E.: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet344:1453-1457,1994
46.
Bloemenkamp Kwm, Rosendaal FR, Helmerhorst FM: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet346: 1593-1596, 1995
47.
sterud B., Robertsen R., Åsvang GB: Resistance to activated protein C is reduced in women using oral contraceptives . Blood Coag Fibrinol5:853-854, 1994
48.
Bertina RM, Reitsma PH, Rosendaal FR: Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost74:449-453, 1995
49.
Guillerm C. , Lellouche F., Darnige L.: Rapid detection of the G1691A mutation of coagulation factor V by PCRmediated site-directed mutagenesis . Clin Chem42:329, 1996
50.
Gandrille S. , Alhenc-Gelas M., Aiach M.: A rapid screening method for the factor V Arg506 → Gln mutation. Blood Coag Fibrinol6:245-248, 1995
51.
Greengard JS , Xu X., Gandrille S.: Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506-factor V. Thromb Res80:441-443, 1995
52.
Rabès JP, Trossaert M., Conard J.: Single point mutation at Arg506 of factor V associated with APC resistance and venous thromboembolism: Improved detection by PCRmediated site-directed mutagenesis. Thromb Haemost74:1397-1387, 1995
53.
Beauchamp NJ , Daly ME, Cooper PC: Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet344:694-695, 1994
54.
Fanning S., O'Meara D., Cotter L.: Detection of the heat-labile toxin coding gene (LT-gene) of enterotoxigenic Escherichia coli, in Walker JM (Ed): PCR in Bioanalysis. Totowa, NJ, Humana Press Publishers, 1997, (in press)
55.
Gibbs RA, Nguyen PN, Caskey CT: Detection of single DNA base differences by competitive oligonucleotide priming . Nucleic Acids Res17:2437-2448, 1989
56.
Peng F., Triplett D., Barna L.: Direct PCR of leukocytes treated with microwave irradiation to detect factor V Leiden mutation. Thromb Res82:193-197, 1996
57.
van de Locht LTF, Kuypers AW, Verbruggen BW: Semi-automated detection of the factor V mutation by allele-specific amplification and capillary electrophoresis . Thromb Haemost74:1276-1279, 1995
58.
Blasczyk R. , Ritter M., Thiede C.: Simple and rapid detection of factor V Leiden by allele-specific PCR amplification. Thromb Haemost74:757-759, 1996
59.
Scobie GA, Ho ST, Dolan G.: Development of a rapid DNA screening procedures for the factor V Leiden mutation . J Clin Pathol: Mol Pathol49:M361-M363, 1996
60.
Lewandowski K., Rozk M., Zawilska K.: Identification of a factor V Leiden mutation by the polymerase chain reaction using sequence-specific primers with an additional mismatch at the 3'-end penultimate position. Br J Haematol93:15, 1996 (abstr)
61.
Brown K., Williamson D., Baglin TP: Detection of the factor VQ506 mutation (factor V Leiden) by allele specific PCR. Br J Haematol93:122, 1996 (abstr)
62.
Petershofen EK, von Widdern O., Bauer I.: Allele-specific tetraprimer PCR assay (ASP) for detection of point mutation G1691A in factor V DNA. Br J Haematol93:15, 1996 (abstr)
63.
Bellissimo DB, Kirschbaum NE, Foster PA: Improved method for factor V Leiden typing by PCR-SSCP. Thromb Haemost75:520-526, 1996
64.
Sherrington PD, Lloyd J., Toh CH: Detection of the factor V Leiden mutation by denaturing gel electrophoresis. Br J Haematol93:22, 1996 (abstr)
65.
Corral J., Iniesta JA, González-Conejero R.: Detection of factor V Leiden from a drop of blood by PCR-SSCP. Thromb Haemost76:735-737, 1996
66.
Catto A., Carter A., Ireland H.: Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol15:783-785, 1995
67.
Emmerich J., Poirier O., Evans A.: Myocardial infarction, Arg506 to Gln factor V mutation and activated protein C resistance. Lancet345:321, 1995
68.
Holm J., Zöller B., Svensson PJ: Myocardial infarction associated with homozygous resistance to activated protein C. Lancet344:952-953, 1994
69.
Kontula K., Ylikorkala A., Miettinen H.: Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost73:558-560, 1995
70.
Ferrer-Antones C., Palmeiro A., Green F.: Polymorphism of fibrinogen, factor VII and factor V genes. Comparison of allele frequencies in different ethnic group . Thromb Haemost73:1379, 1995
71.
Schröder W. , Koessling M., Wulff K.: World distribution of factor V Leiden mutation . Lancet347:58-59, 1996
72.
Pepe G., Rickards O., Vanegas OC: Prevalence of factor V Leiden in non-European populations. Thromb Haemost77:329-331, 1997
73.
Chan LC, Bourke C., Lam CK: Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors— Correlation with absence of Arg506-Gln mutation of the factor V gene. Thromb Haemost75:522-523, 1996
74.
Ko YL, Hsu TS, Wu SM: The G1691A mutation of the coagulation factor V gene (factor V Leiden) is rare in Chinese: An analysis of 618 individuals. Hum Genet98:176-177,1996
75.
Yiqun H., Jiang Z., Liwan X.: Study of the relation between the FV Leiden mutation and Chinese APC resistance . Br J Haematol11, 1996
76.
Fujimura H. , Kambayashi JI, Monden M.: Coagulation factor V Leiden mutation may have a racial background. Thromb Haemost74:1381-1382, 1995
77.
Gou D., Naipal A., Reitsma PH: World distribution of factor V Leiden mutation. Lancet347:59, 1996
78.
de Maat MP, Kluft C., Jespersen J.: World distribution of factor V Leiden mutation. Lancet347:58, 1996
79.
Arruda VR, Annichino-Bizzacchi JM, Costa FF: Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol49:242-243, 1995
